Expert Interview
A 2nd Look at VYD2311, Invivyd’s Investigational Monoclonal Antibody for COVID-19 Prevention and Treatment Ahead of Its Phase 3 Data Readout
Ticker(s): IVVD, PFEInstitution: Stanford University School of Medicine
- Associate Professor of Medicine (Infectious Diseases) and of Microbiology & Immunology at Stanford.
- Manages 60-100 patients annually with complicated urinary tract infections and 50+ Covid patients annually
- Specializes in caring for people with immune responses to infectious disease pathogens, with a research focus on mechanisms of immunity and immunoregulation (including SARS-CoV-2 studies), and clinical trials of immune-modulatory interventions; Leads and collaborates on longitudinal cohort studies and NIH-funded trials on malaria immunology, infant immune development, and immune correlates of protection.
How are you currently managing COVID-19 prevention and treatment in high-risk or immunocompromised patients, and what unmet needs remain?
Added By: sara_adminWhat are your expectations for VYD2311 ahead of the Phase 3 data readout, particularly regarding efficacy against circulating variants and durability of protection?
Added By: sara_adminIn which patient populations do you see the greatest potential role for monoclonal antibodies as pre-exposure prophylaxis for COVID-19?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
